Evidence map›Paper›PMID 36028299›Full record

ArticleBJGP open2022

Dual antithrombotic therapy and gastroprotection in atrial fibrillation: an observational primary care study.

Charis Xuan Xie, John Robson, Crystal Williams, Chris Carvalho, Stuart Rison, Zahra Raisi-Estabragh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJGP open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Charis Xuan XieWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0002-0029-9159
John RobsonNorth East London Integrated Care System, Unex Tower, London, UK.
Crystal WilliamsNorth East London Integrated Care System, Unex Tower, London, UK.
Chris CarvalhoWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Stuart RisonWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0003-3289-6668
Zahra Raisi-EstabraghBarts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK zahraraisi@doctors.org.uk.ORCID https://orcid.org/0000-0002-7757-5465
Queen Mary University of London · GBSt Bartholomew's Hospital · GB

Funding

British Heart Foundation FS/17/81/33318
6 · The paper itself

Abstract

backgroundPatients with both atrial fibrillation (AF) and cardiovascular disease (CVD) may receive dual antithrombotic therapy (DAT) with both an anticoagulant and ≥1 antiplatelet agents. Avoiding prolonged duration of DAT and use of gastroprotective therapies reduces bleeding risk.

aimTo describe the extent and duration of DAT and use of gastroprotection in a primary care cohort of patients with AF. DESIGN &

settingObservational study in 1.2 million people registered with GPs across four east London clinical commissioning groups (CCGs), covering prescribing from January 2020-June 2021.

methodIn patients with AF, factors associated with DAT prescription, prolonged DAT prescription (>12 months), and gastroprotective prescription were characterised using logistic regression.

resultsThere were 8881 patients with AF, of whom 4.7% (

conclusionAlmost two-thirds of patients with AF on DAT were prescribed prolonged durations of therapy. Prescription of gastroprotection therapies was suboptimal in one in six patients. Treatment decisions varied by sex, age, ethnic group, and comorbidity. Duration of DAT and gastroprotection in patients with AF requires improvement.

Indexed as

anticoagulationantiplateletsatrial fibrillationbleeding riskcardiovascular diseasesdual antithrombin therapygastroprotectionpopulation health

Identifiers

PMID36028299
PMCPMC9904777
OpenAlexW4293124976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.